M5 muscarinic receptor Inhibitors
1 drugsAbout M5 muscarinic receptor
The M5 muscarinic receptor is a G protein-coupled receptor that binds acetylcholine, influencing neuronal excitability and synaptic plasticity. Upon activation, it triggers intracellular signaling cascades, playing a role in various physiological processes. Research continues to elucidate its functions.
The M5 receptor is a potential drug target, though there is currently no genetic evidence directly linking it to specific diseases. Further research is needed to validate its role in disease pathology and unlock its full therapeutic potential.
Currently, one FDA-approved drug, darifenacin, interacts with muscarinic receptors and was first approved in 2017. This small molecule drug is marketed by Macleods Pharms Ltd for other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M5 muscarinic receptor Drugs
Macleods Pharms Ltd is the only company with an approved drug targeting this receptor.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
M5 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M5 muscarinic receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics.
M5 muscarinic receptor Clinical Trials 8 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M5 muscarinic receptor Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval was darifenacin in 2017.
A single approval in the past few years indicates a potentially unsaturated market with room for growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting M5 muscarinic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities